Hansa Biopharma: Imlifidase confirms strong Kidney outcome in the US study - Redeye
The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserves a high eGFR level. Hansa does now expect to submit Imlifidase for auS approval in late 2025.
ANNONS
The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserves a high eGFR level. Hansa does now expect to submit Imlifidase for auS approval in late 2025.
